Product
PRX-102
Aliases
pegunigalsidase alfa, PRX-102 1 mg/kg every 2 weeks, PRX-102 1 mg/kg every two weeks, PRX-102 2 mg/kg every 4 weeks, PRX-102 (pegunigalsidase alfa) (1 other aliases)
6 clinical trials
1 indication
Indication
Fabry DiseaseClinical trial
A Multicenter Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Pegunigalsidase Alfa (PRX-102) in Japanese Patients With Fabry Disease (RISE)Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
Multi-centre, Open-label Trial to Assess the saFety, Pharmacodynamics, Efficacy and Pharmacokinetics of pegunigaLsidase Alfa in Patients From 2 Years to Less Than 18 Years of Age With Confirmed FabrY DiseaseStatus: Not yet recruiting, Estimated PCD: 2027-12-01
Clinical trial
A Multi Center Extension Study of PRX-102 Administered by Intravenous Infusions Every 2 Weeks for up to 60 Months to Adult Fabry PatientsStatus: Completed, Estimated PCD: 2020-08-26
Clinical trial
An Open Label Study of the Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)Status: Completed, Estimated PCD: 2019-12-17
Clinical trial
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase BetaStatus: Completed, Estimated PCD: 2021-10-01